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Abstract  
 
In this paper, we present SuHeXiang Wan, a medicine used in traditional 
Chinese medicine for the treatment of epilepsy and convulsions. We 
investigated the antioxidant, anti-inflammatory and neuroprotective 
activities of the same treatment designated as AT000. The synergy of the 
two plants, Dryobalanops aromatica and Saussurea lappa, of which the use 
in alimentary supplements is considered controversial, was evaluated for 
the first time. The antioxidant activity of the extract was assessed by DPPH 
and ORAC tests while the anti-inflammatory activity was determined by 
measuring the capacity of macrophages to generate a strong inflammatory 
response when stimulated with antigens, inducing NO release. The extract 
efficacy on the attenuation of the Aβ25-35-induced learning deficits (spatial 
working memory: spontaneous alternation in the Y-maze and contextual 
long-term memory: passive avoidance test) was evaluated in vivo in mice 
seven days after the peptide administration. The impact on lipid 
peroxidation in the hippocampus, an index of oxidative  
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stress, was also evaluated. AT000 extract showed a strong antioxidant 
activity at 2 mg/mL, 10 mg/mL and 301774 Trolox equivalents according 
to the DPPH and ORAC tests respectively. The 21-days AT000 treatment 
dose-dependently alleviated Aβ25-35-induced deficits, with significant 
prevention at the highest dose tested (250 mg/Kg/day) on the spontaneous 
alternation, step-through latency and escape latency parameter. 21-days 
AT000 treatment dose-dependently attenuated also Aβ25-35-induced 
increase lipid peroxidation, with a significant and complete blockade at the 
highest doses tested. Synergistic experiments showed that the presence of 
Dryobalanops aromatica and Saussurea lappa is crucial to obtain a 
neuroprotective effect. According to these results, AT000 could be a 
candidate compound in the development of therapeutic drugs for the 
prevention and treatment of Alzheimer’s disease.  
 
1. Introduction 
Alzheimer's disease (AD) is an incurable 
neurodegenerative disease of cerebral tissue that 
leads to progressive and irreversible loss of mental 
functions and especially memory. It is the most 
common cause of dementia in humans [1].  AD is 
characterized by two primary lesions: senile 
plaques which are toxic extracellular aggregates of 
amyloid peptides and neurofibrillary tangles which 
are intracellular aggregates formed of pairs of 
helical filaments due to the abnormal formation of 
hyperphosphorylated tau protein masses [2]. The 
clinical symptoms of this disease include memory 
loss [3], especially recent events in the early phases 
of the disease and deterioration of other cognitive 
functions that interfere with mood, reasoning, 
judgment and language [4, 5]. 
From a histopathological point of view, 
abnormal cleavage by beta-secretase of amyloid 
precursor protein leads to the extracellular 
accumulation of neurotoxic peptide Aβ42 
generating senile plaques which compress neurons 
[6]. Oligomeric peptides Aβ play a significant role 
in mediating neurotoxicity and leading to AD [7]. 
They provoke strong alterations of plasticity 
mechanisms leading to a decline in memory [8, 9].   
Oligomers of Aβ peptides vary in length 
between 40 and 43 amino acids. Aβ40 and Aβ42 are 
the most abundant species found in AD brains [10], 
however only the Aβ42 fragment forms fibrillar 
deposits readily [11]. Another toxic minor 
fragment Aβ25-35 has also been identified and used 
widely in research [12, 13]. Aβ oligomers interact 
with the intracellular organelles responsible for the 
regulation of calcium homeostasis leading to 
oxidative stress and causing neuronal apoptosis 
[14]. Aβ peptides can also provoke an 
inflammatory response in the brain and cytokine 
production by active astrocytes and microglia [15]. 
Several studies have shown the presence of 
lipids and proteins oxidation products in the tissues 
of Alzheimer's patients after death [16]. Further 
studies suggested the presence of a link between 
increased oxidative stress promoted by Aβ and the 
presence of senile plaques [17].   
Despite scientific advances in this field, at 
present, there is no effective treatment to inhibit the 
progression of the disease and stop the cognitive 
decline. Since brain lesions (amyloid plaques and 
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neurofibrillary degeneration) trigger a decrease in 
the neurotransmitter acetylcholine that allows 
neurons to communicate. Drug treatment options 
are currently limited to acetylcholine esterase 
inhibitors. Anticholinesterasics include three 
different molecules that have been rigorously tested 
and have proven to be effective in mild-to-
moderate forms of the disease: Donepezil, 
Galantamine and Rivastigmine [18]. These 
treatments help to stabilize the disease, however; 
they do not reverse it nor cure it. In addition, these 
molecules can interact with a wide range of drugs 
and their consumption is associated with numerous 
side effects [19].  
In non-drug therapies, to alleviate the 
symptoms of AD and improve cognitive functions, 
plants were used. The advantage of medicinal 
plants is their richness in compounds, which can act 
synergistically with other compounds from the 
same or another plant. plant-derived molecules can 
also boost the activity of the constituents or 
neutralize the toxic effects of compounds from 
other plant species [20]. Today, traditional Chinese 
medicine is a potential alternative to drug 
treatments. By testing different combinations of 
plants having potential neuroprotective activities, 
several studies in this field have shown that plant 
extracts derived from traditional Chinese medicine 
help fight against the symptoms of 
neurodegenerative diseases such as AD [21-24]. 
SuXeHiang Wan, an extract of 9 plants that 
have been used in the treatment of epilepsy and 
convulsions, has demonstrated a sedative and 
anticonvulsant effect as well as inhibitory effects 
on the central nervous system following the 
inhalation of its Essential oil [24]. In mice, the 
essential oil, SuXeHiang Wan, was shown to 
attenuate the amyloid beta-induced alteration of 
memory by inhibiting the phosphorylation of tau 
protein [25]. This extract contains an unlisted plant 
in the French Pharmacopoeia (Dryobalanops 
aromatica) and another plant which its roots are 
declared in mutual recognition in the list B of 
French pharmacopoeia (Saussurea lappa). In the 
present study, the same extract designated as 
AT000 was evaluated for its antioxidant, anti-
inflammatory and cytotoxic activities. We also 
investigated whether the oral administration of 
AT000 mixture can alleviate the pathology induced 
in mice injected intracerebroventricularly (i.c.v) 
with oligomeric amyloid-β25-35 peptide (Aβ25-35). In 
addition, this study evaluated for the first time the 
synergistic effect of Dryobalanops aromatica and 
Saussurea lappa in vivo. 
 
2. Materials and Methods 
2.1 Materials 
All medicinal plants were purchased from 
GIVAUDAN Shanghai-China. 2,2-diphenyl-1-
picrylhydrazyl radicals (DPPH), N,O-Bis 
(trimethylsilyl) trifluoroacetamide (BSTFA), 
phosphate buffer, fluorescein, 2,2’-azobis (2-
amidino-propane) dihydrochloride (AAPH), 
dimethyl sulfoxide (DMSO), Propyl gallate, 
Ascorbic acid, Griess modified reagent, 
Dexamethasone, RAW 264.7 cells, and 
Lipopolysaccharides (LPS) of E.coli, were 
purchased from Sigma-Aldrich (St Louis USA). 
Trolox was obtained from Calbiochem (San Diego, 
United States), Dulbecco’s modified Eagle 
Minimum Essential Medium (DMEM), 
Penicillin/streptomycin and inactivated calf serum 
were purchased from PAN BIOTECH. Aβ25-35 and 
scrambled amyloid-β protein (25-35) Sc.Aβ were 
purchased from Polypeptides (France). 
 
2.2 Preparation of plant extract 
AT000 was prepared as described previously 
with some modifications [24]. A total of 175 g of 
the mixture of Liquidambar orientalis (20 g), 
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Saussurea lappa (20 g), Aquilaria agallocha (15 
g), Santalum album (20 g), Boswellia carteri (20 
g), Eugenia caryophyllata (20 g), Cyperus 
rotundus (20 g), Styrax benzoin (20 g), and 
Dryobalanops aromatica (20 g), was pulverized 
and extracted once with 10 vol. of water/ethanol 
mixture (70:30, v/v) at 80-85 °C with reflux 
condenser for 3 hours. The extract was then 
vacuum filtered using a Büchner flask and 
evaporated using a rotary evaporator at 60 °C to 
give a sticky brown oil. To evaluate the impact of 
Dryobalanops aromatica and Saussurea lappa, we 
made 4 different extracts designed as AT 
formulations in the following manner: 
AT001: Dryobalanops aromatica 
AT002: Dryobalanops aromatica + Saussurea 
lappa  
AT007: AT000 without Dryobalanops aromatica 
and Saussurea lappa  
AT008: AT000 without Dryobalanops aromatica 
 
2.3 Determination of radical scavenging activity 
The radical scavenging activity of the extract 
was determined by measuring its ability to trap the 
stable free radical, DPPH as described by Brand-
Williams et al. with some modifications [26]. 
Briefly, 0.05 mM solution of DPPH˙ was prepared 
in methanol, and 2.9 mL of this solution was added 
to 0.1 mL extract solution in methanol at different 
concentrations (from 0.2 to 10 mg/mL). The 
reaction mixture was stirred at room temperature in 
a dark chamber for 30 minutes, and the absorbance 
was recorded at 517 nm using a UV-Vis 
spectrophotometer (Ultrospec 3000 pro). Control 
was prepared by adding 2.9 mL of the DPPH 
solution (0.05 mM) to 0.1 mL of methanol. IC50 
values, which represent the concentration of the 
extract that causes neutralization of 50% of the 
DPPH radicals, were calculated from the 
percentage inhibition (PI, %) versus concentration 
curve as Eq. (1). The inhibition of free radicals by 
DPPH (%) was calculated using the following 
equation:   
PI (%) = [1–(A1/A0)] x 100                                           (1) 
Where A0 is the absorbance of the control reaction 
and A1 is the absorbance in the presence of the 
sample. Trolox, ascorbic acid and propyl gallate 
were used as positive controls. Measurements were 
performed in triplicate, and the corresponding 
standard deviation was calculated. 
 
2.4 Oxygen Radical Absorbance Capacity Assay 
The oxygen radical absorbance capacity 
(ORAC) assay was assessed in microplates as 
described by Ou et al. with some modifications 
[27]. The plant extract, AAPH, and fluorescein 
were diluted in 100 mM potassium phosphate 
buffer (pH 7.4). 25µL of each extract (0.94-7.5 
µg/mL) or phosphate buffer (blank) were mixed 
with 150 µL of fluorescein solution (8.21 x 10-5 
mM) and incubated for 15 min at 37 °C. A volume 
of 25 µL of AAPH solution (153 mM final 
concentration) was added, and fluorescence was 
immediately monitored using an Infinite M200 
TECAN plate fluorimeter at 2-min intervals for 90 
min. the excitation and emission wavelengths used 
are 485 nm and 530 nm respectively. A calibration 
curve was performed with Trolox (0.4−12.5 µM) as 
standard. The ORAC values were calculated using 
the neat AUCs and expressed as µmol of Trolox 
equivalent per 100g of extract (μmol TE/100g). 
Trolox was used as a control standard. 
 
2.5 Cell culture 
Mouse macrophages cells (RAW 264.7) were 
maintained in DMEM with stable L-glutamine 
supplemented with Penicillin 100 IU/mL, 
streptomycin 100 μg/mL and 10% of inactivated 
calf serum at pΗ 7.2, freshly prepared, stored no 
longer than 3 weeks. 
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2.6 Anti-inflammatory and cytotoxicity assays 
In vitro anti-inflammatory assay was 
determined by measuring the capacity of 
macrophages to generate a robust inflammatory 
response when stimulated with antigens, inducing 
NO release [28]. Cells were seeded into 48-well 
tissue culture plates at a concentration of 1.105 
cells/mL (200 µL/well) for 24 hours at 37 °C (5% 
CΟ2). Then the culture medium was replaced by 
200 µL of medium containing the appropriate 
concentrations of AT000 extract, and cells were 
incubated at 37 °C in a humidified atmosphere of 
5% CO2/90% air for one hour. At the end of the 
incubation period, pro-inflammatory LPS from E. 
coli were added to cell cultures (1 µg/mL), and cells 
were incubated under the same conditions for 24 
hours. NO release was evaluated indirectly by 
measuring the accumulation of nitrite/nitrate, the 
stable end-products of NO oxidation, in the culture 
supernatant by the Griess reaction. 100 µL of the 
supernatants were transferred into the wells of a 96-
well tissue culture plate, and 100 µL of the Griess 
modified reagent were added to each well. After 
15-min at room temperature, the Optical Density 
(OD) of each well was read at 540 nm by a 
fluorescence-luminescence reader Infinite M200 
Pro (TECAN). The results obtained for wells 
treated with AT000 extract were compared to those 
of untreated control wells (DMSO, 100% viability) 
and converted to percentage values.  
In parallel to the assessment of NO release, 
cell viability was measured to validate the assay. 
The WST-1 vital dye reagent was used to measure 
cell mitochondrial respiration. For this purpose, the 
culture medium was decanted, and 100 µL of WST-
1 reagent (1/10 dilution) was added to each well. 
After a 30-min incubation period at 37 °C (5% 
CO2), the Optical Density (OD) of each well was 
read at 450 nm by a fluorescence-luminescence 
reader Infinite M200 Pro (TECAN). The results 
obtained for wells treated with AT000 extract were 
compared to those of untreated control wells 
(DMSO, 100% viability) and converted to 
percentage values. Experiments were performed in 
duplicate and dexamethasone was used as a 
positive control at the concentrations of 1, 5, 10, 50 
and 100 μM. 
Inhibition of NO release and inhibition of cell 
viability were expressed as percentages as 
compared to the negative controls: 
PI (%) = 100 x (ODtest well - ODblank)/(ODcontrol-
ODblank)                                                               (2) 
The concentrations of the extract causing 
respectively a 50% decrease of NO release (IC50-
NO-R) and a 50% decrease of cell viability (IC50-cell-
V) were calculated through non-linear regression 
analysis using software TableCurve Version 2.0. 
The anti-inflammatory ratio corresponded to the 
ratio between the anti-inflammatory activity and 
the toxicity. It was expressed as follows: 
Anti-inflammatory ratio = IC50-cell-V/IC50-NO-R      (3) 
 
2.7 Animal studies 
Male Swiss mice, six weeks old, weighing 
30-35 g, from JANVIER (Saint Berthevin, France), 
were kept for housing. Experiments took place 
within the animal facility building of the University 
of Montpellier 2 (CECEMA, Office of Veterinary 
Services agreement # B- 34-172-23) for 
experiments 1-2 and in Amylgen (Regional 
Directorate of Food, Agriculture and Forest of 
Languedoc-Roussillon, agreement #A 34-169-002 
from May 02, 2014) for experiments 3. Animals 
were housed in groups with access to food and 
water ad libitum, except during behavioral 
experiments. They were kept in a temperature and 
humidity controlled animal facility on a 12 h/12 h 
light/dark cycle (lights off at 07:00 pm). Mice were 
numbered by marking their tail using permanent 
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markers. All animal procedures were conducted in 
strict adherence to the European Union directive of 
September 22, 2010 (2010/63/UE).  
 
2.7.1 Drugs and administration procedures 
The homogeneous oligomeric preparation of 
Aβ25-35 peptide and scrambled Aβ25-35 peptide 
(Sc.Aβ) was performed according to the 
AMYLGEN's owned procedure. The preparations 
were dissolved in distilled sterile water at a 
concentration of 3 mg/mL and stored at -20 °C until 
use. Before injection, peptides were aggregated by 
incubation at 37 °C for 4 days. Each mouse was 
anesthetized with isoflurane 2.5% and injected 
i.c.v. with Aβ25-35 peptide (9 nmol/mouse) or Sc.Aβ 
peptide (9 nmol/mouse), in a final volume of 3 µL 
per mouse, according to the previously described 
method [29-33].  
Two administration procedures were 
examined. In experiment 1, AT000 was 
administered per os (p.o.) by gavage twice-a-day 
(b.i.d.), starting on the same day as Aβ25-35 and 
lasting until day 7 when the animals’ behaviors 
were examined (7-days injection). In experiment 2, 
AT000 was administered per os by force-feeding 
twice-a-day (b.i.d.), starting 14 days before Aβ25-35 
injection and lasting until day 7 when the animals’ 
behaviors were examined (21-days injection). 
Finally, a third experiment was performed to 
analyze the impact of the two controversial plants 
in the extract: Dryobalanops aromatica and 
Saussurea lappa. This last experiment was 
performed at the active dose of the 21-days 
injection procedure.  
 
2.7.2 Animals and treatment groups  
• Two hundred and forty (240) male Swiss mice 
(30-35 g) were used. 
• Twenty (20) groups of animals were constituted 
in the following manner:    
Experiment 1 (groups 1-5): 
• On day 0, Sc.Aβ or Aβ25-35-amyloid peptide was 
injected i.c.v. at 10:00 am. 
• Between day 0 and day 9, AT000 or the vehicle 1 
solution (DMSO 5% in water) was administered 
p.o. by force-feeding b.i.d., at 09:00 am and 05:00 
pm. AT000 was administered only once at 09:00 
am on day 9. 
Experiment 2 (groups 6-10): 
• Between day -14 and day 9, AT000 or the vehicle 
1 solution (DMSO 5% in water) was administered 
p.o. by force-feeding b.i.d., at 09:00 am and 05:00 
pm. AT000 was administered only once at 09:00 
am on day 9.  
• On day 0, Sc.Aβ or Aβ25-35-amyloid peptide was 
injected i.c.v. at 10:00 am. 
Experiment 3 (groups 11-20): 
• On day 0, Sc.Aβ or Aβ25-35-amyloid peptide was 
injected i.c.v. at 10:00 am. 
• Between day -14 and day 9, AT000, AT001, 
AT002, AT007, AT008 or the vehicle solutions 
(vehicle 1 = DMSO 5% in water; vehicle 2 = 
DMSO 10% in grapeseed oil) was administered 
p.o. by force-feeding b.i.d., at 09:00 am and 05:00 
pm.  
Then, for all groups: 
• On day 7, all animals were tested for the 
spontaneous alternation performance in the Y-
maze test, an index of spatial working memory. 
• On day 8 and 9, the contextual long-term memory 
of the animals was assessed using the step-through 
type passive avoidance procedure. 
• On day 9, immediately after the retention session, 
animals were euthanized by decapitation and the  
hippocampus and cortex dissected out. Lipid 
peroxidation in the hippocampus was analyzed.  
 
2.7.3 Formulation preparation 
All solutions were freshly prepared twice a 
day before each injection as listed in Table 1. No 
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stock solution was prepared. Solutions were 
prepared from an initial concentrated solution in 
DMSO 100%. Then dilution was done in distilled 
water. Final DMSO concentration was 5%. 
Groups 1, 2, 6, 7, 11, 12: vehicle 1 solution (DMSO 
5% in water). 
Groups 3, 8: AT000 6.2 mg/mL in vehicle 1 
solution (corresponding to 37.5 mg/kg b.i.d. or 62.5 
mg/kg/day). 
Groups 4, 9: AT000 12.5 mg/mL in vehicle 1 
solution (corresponding to 62.5 mg/kg b.i.d. or 125 
mg/kg/day). 
Groups 5, 10: AT000 25 mg/mL in vehicle 1 
solution (corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
Groups 14, 15: vehicle 5 solution (DMSO 10% in 
grapeseed oil plus emulsifier). 
Group 16: AT000 25 mg/mL in vehicle 2 solution 
(corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
Group 17: AT001 25 mg/mL in vehicle 2 solution 
(corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
 
Table 1. Groups of animals, treatment period and number of mice used for different experiments. 
Experiment 
Groups of animals 
Number 
of days 
Number 
of mice 
Experiment 1 
1 Sc.Aβ + vehicle 1 7 12 
2 Aβ25-35 + vehicle 1 7 12 
3 Aβ25-35 + AT000: 62.5 mg/kg/day 7 12 
4 Aβ25-35 + AT000: 125 mg/kg/day 7 12 
5 Aβ25-35 + AT000: 250 mg/kg/day 7 12 
Experiment 2 
6 Sc.Aβ + vehicle 1 21 12 
7 Aβ25-35 + vehicle 1 21 12 
8 Aβ25-35 + AT000: 62.5 mg/kg/day 21 12 
9 Aβ25-35 + AT000: 125 mg/kg/day 21 12 
10 Aβ25-35 + AT000: 250 mg/kg/day 21 12 
Experiment 3 
11 Sc.Aβ + vehicle 1 21 12 
12 Aβ25-35 + vehicle 1 21 12 
13 Aβ25-35 + AT000 (in vehicle 1): 250 mg/kg/day 21 12 
14 Sc.Aβ + vehicle 2 21 12 
15 Aβ25-35 + vehicle 2 21 12 
16 Aβ25-35 + AT000 (in vehicle 2): 250 mg/kg/day 21 12 
17 Aβ25-35 + AT001: 250 mg/kg/day 21 12 
18 Aβ25-35 + AT002: 250 mg/kg/day 21 12 
19 Aβ25-35 + AT007: 250 mg/kg/day 21 12 
20 Aβ25-35 + AT008: 250 mg/kg/day 21 12 
 
Group 18: AT002 25 mg/mL in vehicle 2 solution 
(corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
Group 19: AT007 25 mg/mL in vehicle 2 solution 
(corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
 Iskandar et al., Chemistry of Advanced Materials 3(2) (2018) 36-59   
 
 
43 
 
Group 20: AT008 25 mg/mL in vehicle 2 solution 
(corresponding to 125 mg/kg b.i.d. or 250 
mg/kg/day). 
 
2.7.4 Euthanization  
At the end of the passive avoidance retention 
session, on day 9, animals were euthanized by 
decapitation. The hippocampi and frontal cortex 
were removed. One hippocampus of n=6 animals 
per group was used to measure lipid peroxidation 
levels in tissue extracts. The other hippocampus 
and the cortex were kept at -80 °C awaiting further 
analysis. 
 
2.7.5 Spontaneous alternation performances 
On day 7, all animals were tested for 
spontaneous alternation performance in the Y-
maze, an index of spatial working memory. The Y-
maze was made of grey polyvinylchloride. Each 
arm was 40 cm long, 13 cm high, 3 cm wide at the 
bottom, 10 cm wide at the top, and converging at 
an equal angle. Each mouse was placed at the end 
of one arm and allowed to move freely through the 
maze during an 8-min session. The series of arm 
entries, including possible returns into the same 
arm, was checked visually. An entry was defined as 
the penetration of the hind paws of the animal at 
least 2 cm into the arm. An alternation was defined 
as entries into all three arms on consecutive 
occasions. The number of maximum alternations 
was the total number of arm entries minus two and 
the percentage of alternation was calculated as: 
actual alternations/maximum alternations) x 100. 
Parameters included the percentage of alternation 
(memory index) and the total number of arm entries 
(exploration index) [29-33]. 
 
2.7.6 Passive avoidance test 
The apparatus is a two-compartment (15 x 20 
x 15 cm high) box, one illuminated with white 
polyvinylchloride walls and the other darkened 
with black polyvinylchloride walls and a grid floor. 
A guillotine door separates each compartment. A 
60 W lamp positioned 40 cm above the apparatus 
lights up the white compartment during the 
experiment. Scrambled foot shocks (0.3 mA for 3 
s) were delivered to the grid floor using a shock 
generator scrambler (Lafayette Instruments, 
Lafayette, USA). The guillotine door was initially 
closed during the training session. On day 8, during 
the training session, each mouse was placed in the 
white compartment. After 5 s, the door was raised. 
When the mouse entered the darkened 
compartment and placed all its paws on the grid 
floor, the door was closed and the foot shock 
delivered for 3 s. The step-through latency, that is, 
the latency spent to enter the darkened 
compartment, and the number of vocalizations was 
recorded. The retention test was carried out 24 h 
after training, on day 9. Each mouse was placed in 
the white compartment again. After 5 s, the door 
was raised. The step-through and escape latencies 
(corresponding to the re-exit from the darkened 
compartment) were recorded up to 300 s [31-33]. 
Animals that showed all latencies during the 
training and retention session lower than 10 s were 
considered as having failed to respond to the 
procedure and were discarded from the 
calculations. In this study, no animal was discarded 
accordingly. 
2.7.7 Lipid peroxidation measures  
At day 9, 6 mice from each group were 
euthanized by decapitation, and both hippocampi 
were rapidly removed, weighed and kept in liquid 
nitrogen until assayed. After thawing, one 
hippocampus per mice was homogenized in cold 
methanol (1/10 w/v), centrifuged at 1,000 g for 5 
min and the supernatant placed in Eppendorf tube. 
The reaction volume of each homogenate was 
added to FeSO4 1 mM, H2SO4 0.25 M, xylenol 
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orange 1 mM and incubated for 30 min at room 
temperature. After reading the absorbance at 580 
nm (A5801), 10 µL of cumene hydroperoxide (CHP) 
1 mM was added to the sample and incubated for 
30 min at room temperature, to determine the 
maximal oxidation level. The absorbance was 
measured at 580 nm (A5802). The level of lipid 
peroxidation was determined as CHP equivalents 
according to CHPE = A5801/A5802 x [CHP (nmol)] 
and expressed as CHP equivalents per mg of tissue 
and as a percentage of control group data (V-treated 
Sc.Aβ-administered mice). 
 
2.7.8 Statistical analyses  
All values, except passive avoidance 
latencies, were expressed as mean ± S.E.M. 
Statistic analyses were performed on the different 
conditions using one-way ANOVA (F value), 
followed by the Dunnett’s post-hoc multiple 
comparison tests. Passive avoidance latencies do 
not follow a Gaussian distribution since upper cut-
off times were set. Therefore, they were analyzed 
using a Kruskal-Wallis non-parametric ANOVA 
(H value), followed by a Dunn's multiple 
comparison tests. p < 0.05 was considered as 
statistically significant.  
 
3. Results and Discussion 
3.1 Antioxidant activity 
To determine the antioxidant potential of our 
extract, we evaluated the reducing power by the 
widely used DPPH test, and the ability to delay the 
oxidation of fluorescein by the ORAC assay. 
DPPH˙ is a stable radical, nitrogen-centered and 
colored due to the delocalization of electron with a 
visible absorption maximum at 517 nm in an 
alcoholic solution. The reduction of the DPPH 
radical by the antioxidant compound is manifested 
by a decrease in the absorbance of the DPPH 
radical and by its discoloration (from violet to 
yellow) [34]. The ORAC assay is currently 
considered the most relevant chemical test for 
measuring antioxidant activity since it is a dynamic 
test based on stress induced by peroxyl radicals 
mimicking the cellular mechanisms induced by 
them [35, 36]. The DPPH scavenging effect of 
AT000 extract increased with increasing 
concentration of extract (Fig. 1), which 
demonstrated strong antioxidant ability at 2 mg/mL 
and 10 mg/mL (82.08 and 93.39%) respectively. 
Table 2 shows the antioxidative potency of AT000 
extract compared with foods known to have 
substantial antioxidant activity (USDA Database 
for ORAC): Nutrient Data Laboratory, Agriculture 
Research Service, United States Department of 
Agriculture). AT000 extract exhibited a powerful 
antioxidant activity with a value of 301774 Trolox 
equivalents compared to the reference compounds. 
This strong antioxidant activity is due to the 
richness of the plants constituting AT000 extract in 
phenolic compounds having the capacity to trap 
free radicals. Eugenol, the main component 
isolated from Eugenia caryophyllata possesses 
potent antioxidant properties [37, 38]. The 
ethanolic extract of Liquidambar orientalis leaves 
also showed a high antioxidant activity [39]. Ethyl 
acetate extract of Aquilaria agallocha have been 
reported to have free radical scavenging activity 
[40], and antioxidant properties in vitro at different 
concentrations by inhibition of nitrite-induced 
oxidation of hemoglobin in human blood 
hemolysate [41]. 
 Iskandar et al., Chemistry of Advanced Materials 3(2) (2018) 36-59   
 
 
45 
 
Figure 1. Free radical scavenging activity of 
methanol extract of AT000, trolox, propyl gallate, 
and ascorbic acid by 2,2-diphenyl-1- 
picrylhydrazyl radicals.  
 
Table 2. ORAC values of AT000 and foods 
expressed as µmol Trolox Eq. (μmol/100g) 
Sample Trolox Eq. 
(μmol/100 g) 
AT000  301774 
Ground cloves spice 290283 
Indian gooseberry, dried 261500 
Oregano spice, dried 175295 
Rosemary spice, dried 165280 
Cinnamon spice, ground 131420 
 
Coumarins, tannins, and flavonoids isolated 
from Cyperus rotundus tuber extracts exhibited 
antibacterial, antioxidant, antimutagenic, cytotoxic 
and apoptotic properties [42, 43]. Cyanidin-3-
glucoside, the primary pigment identified in 
Santalum album berries extract possessed 
antioxidant potentials and high scavenging activity 
[44]. This combination of molecules acts 
synergistically to boost the overall antioxidant 
activity of the extract. 
 
3.2 Anti-inflammatory and cytotoxicity assays  
Anti-inflammatory activity and cytotoxicity 
of AT000 extract were tested in vitro and compared 
to dexamethasone as a positive control. The results 
are summarized in Table 3. AT000 showed the 
release of NO with IC50 value < 20 μM on 
macrophages RAW 264.7 and exhibited 
cytotoxicity with IC50 value > 50 μM.  
Aging is characterized by inflammation involved in 
the pathogenesis of all age-related diseases such as 
AD along with increased expression of 
inflammatory mediators [45]. this chronic 
inflammation is stimulated by Aβ plaques and 
tangles [46]. The hallmark of the inflammatory 
state is the increase of serum levels of 
inflammatory mediators such as cytokines [47, 48], 
free radicals as reactive oxygen species and nitric 
oxide [49, 50]. AT000 extract showed an effective 
anti-inflammatory activity compared to 
dexamethasone, by inhibiting NO release from 
LPS-stimulated murine mouse macrophages RAW 
264.7 cells and reduced LPS-induced cytotoxicity 
(Table 3). The plants constituting AT000 extract 
are rich in molecules with high anti-inflammatory 
properties; Eugenol has shown an anti-
inflammatory activity by suppressing the 
expression of cyclooxygenase-2 in mouse 
macrophage cells stimulated with 
lipopolysaccharide (LPS) [51].  Aquilaria 
agallocha oil demonstrated anti-inflammatory 
activity, thus significantly reducing edema in 
carrageenan-induced paw edema model [52]. 
Triterpene acids isolated from Boswellia carteri 
resin demonstrated potent anti-inflammatory 
activity in the mouse ear edema assay [53]. 
Delivery of Boswellia resin extract resulted in a 
dose-dependent inhibition of TH1 cytokines 
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coupled with a dose-dependent potentiation of TH2 
cytokines indicating that purified mixture of BAs 
from Boswellia carteri plant resin exhibits carrier-
dependent immunomodulatory properties in vitro 
[54]. Extract of rhizomes of Cyperus rotundus 
increased HO-1 expression in a concentration-
dependent manner, which was correlated with 
significant inhibition of iNOS/NO production in 
LPS-activated RAW 264.7 cells [55]. α-Cyperone, 
the primary compound isolated from the rhizomes 
of Cyperus rotundus, inhibits LPS-induced COX-2 
expression and PGE2 production through the 
negative regulation of NFκB signalling in RAW 
264.7 cells [56]. The (9R,10E)-9-hydroxy- α -
santalal, a sesquiterpene isolated from Santalum 
album exhibited tumor-selective cytotoxicity 
against HL-60 cells [57]. Cyclosaplin, A new cyclic 
octapeptide purified from somatic seedlings of 
Santalum album L. exhibited cytotoxic activity 
against cultured human breast cancer (MDA-MB-
231) cell line, by inducing apoptotic cell death by 
caspase 3 activation [58]. Saussurea lappa 
exhibited inhibitory effects on IL-8 Induction in 
Lipopolysaccharide-Activated Rat Macrophages 
[59]. Ethanolic extract of Saussurea lappa affects 
acute and chronic inflammation induced in mice 
and rats by inhibiting carrageenan-induced paw 
edema and preventing accumulation of 
inflammatory cells in carrageenan-induced 
peritonitis in vivo [60]. ‘Dehydrocostus lactone’, a 
sesquiterpene lactone from Saussurea lappa 
suppressed LPS-induced nitric oxide production 
[61] and inhibited release of TNF-α [62]. Another 
sesquiterpene lactone ‘cynaropicrin’ from 
Saussurea lappa inhibited TNF-α murine 
macrophage cell line and dose-dependently 
suppressed the proliferation of lymphocytes 
stimulated by Con-A [63]. Santamarin, a 
sesquiterpene lactone isolated from Saussurea 
lappa, represses LPS-induced inflammatory 
responses via expression of heme oxygenase-1 in 
murine macrophage cells [64]. Borneol, the main 
component isolated from Dryobalanops aromatica 
inhibit nicotinic receptor-mediated catecholamine 
secretion in bovine adrenal chromaffin cells [65, 
66]. All these properties add up to demonstrate the 
anti-inflammatory activity of AT000 extract. 
 
3.3 AT000 extract recovers cognitive functions in 
Aβ25-35-treated mice 
To determine the effective dose and the optimal 
injection time of the extract, the neuroprotective 
effect of AT000 was examined on the attenuation 
of the Aβ25-35-induced learning deficits according 
to two administration procedures (7-days and 21-
days injection).  
 
3.3.1 Spontaneous alternation performances 
The spatial working memory was first 
examined by evaluating spontaneous alternation in 
the Y-maze test. As shown in Fig. 2a and 2c, the 
Aβ25-35 treatment induced highly significant 
spontaneous alternation deficits as compared to 
Sc.Aβ/V-injected mice. The 7-days AT000 
treatment tended to attenuate the Aβ25-35-induced 
deficits, but no significant effect vs. Aβ25-35-treated 
animals was noted (Fig. 2a). No effect was noted 
on locomotion (Fig. 2b). On the other hand, the 21-
days AT000 treatment prevented the Aβ25-35-
induced deficits at the highest dose tested (250 
mg/Kg/day) with a highly significant effect vs. the 
Aβ25-35 treated group (Fig. 2c). A mild effect was 
noted on locomotion since the ANOVA was 
significant, but no group effect was observed (Fig. 
2d). Compared to 21-days pre-treatment, the daily 
injection of AT000 extract starting on the same day 
as Aβ25-35 injection and lasting 7 days after, reduced 
Aβ25-35-induced deficits at 250 mg/kg/day but 
without having a significant effect on spontaneous 
alteration in the Y-maze (Fig. 2a, b). This result 
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indicates that the extract acts according to a 
preventive way and not the curative way. In the 
case of a preventive treatment, the optimal effect 
was observed with increased treatment duration. 
The hypothesis is that the extract administered as a 
prolonged treatment induces a modification in the 
neurons, which makes the nervous system more 
resistant and less sensitive to aggression by Aβ25-
35-induced toxicity. Treatment for 21 days produces 
a more significant effect than 7 days treatment 
because it has more time to induce these 
modifications which are still poorly understood. 
 
 
Table 3. Anti-inflammatory, cytotoxic activity and the anti-inflammatory ratio of AT000 and 
Dexamethasone. 
 NO release IC50 (µM) Toxicity IC50 (µM) Anti-inflammatory ratio 
AT000 (10 mg/mL) 
Dexamethasone 
1.06 
4.31 + 1.45 µM 
> 50.00 
163.22 + 74.96 µM 
> 47.00 
37.87 
 
 
Figure 2. Effects of AT000 p.o. administration during 7 days (a, b) and 21 days (c, d) on Aβ25-35-induced 
spontaneous alternation deficits in mice. V, vehicle solution. *** p < 0.001, * p < 0.05 vs. the V-treated 
Sc.Aβ group; ### p < 0.001 vs. the Aβ25-35 treated group; Dunnett's test.  
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3.3.2 Step-through passive avoidance test 
The contextual long-term memory was evaluated 
using the step-through passive avoidance test. The 
Aβ25-35 treatment led to highly significant passive 
avoidance deficits as compared to Sc.Aβ/V-
injected mice, both regarding step-through latency 
(Fig. 3a, c) and escape latency (Fig. 3b, d) during 
the retention session. The 7-days AT000 treatment 
alleviated the Aβ25-35-induced deficits, with 
important prevention at the highest dose tested (250 
mg/Kg/day) on the step-through latency parameter 
(Fig. 3a). However, the 21-days AT000 treatment 
dose-dependently alleviated the Aβ25-35-induced 
deficits, with a significant prevention at the highest 
dose tested (250 mg/Kg/day) on both the step-
through latency (Fig. 3c) and escape latency 
parameter (Fig. 3d). Note that the treatments did 
not affect the step-through latency or shock 
sensitivity during the training session. 
 
3.3.3 Lipid peroxidation measure 
Lipid peroxidation, one of the essential 
biochemical parameters of amyloid toxicity, was 
also analyzed in the hippocampus to validate the 
neuroprotective activity of the extract. According 
to the 7-days AT000 injection procedure, Aβ25-35 
treatment induced highly significant increase 
(+87%) in lipid peroxidation in the hippocampus, 
as compared to Sc.Aβ/V-injected mice (Fig. 4a). 
The 7-days AT000 treatment dose-dependently 
attenuated the Aβ25-35-induced increase, with a 
significant effect at the two highest doses tested 
(125 and 250 mg/Kg/day) (Fig. 4a). At 250 
mg/kg/day, the lipid peroxidation level remained 
significantly higher than Sc.Aβ/V-injected mice 
(+29%). According to the 21-days AT000 injection 
procedure, Aβ25-35 treatment induced highly 
significant increase (+33%) in the level of 
peroxidized lipids in the hippocampus, as 
compared to Sc.Aβ/V-injected mice (Fig. 4b). The 
21-days AT000 treatment dose-dependently 
attenuated the Aβ25-35-induced increase, with a 
significant and complete blockage at the highest 
doses tested (Fig. 4b). 
The pre-treatment by oral administration of 
AT000 extract for 21 days, alleviated the pathology 
induced intracerebroventricularly in mice and 
showed significant activity on the attenuation of 
Aβ25-35-induced learning deficits, with a highly 
significant effect at 250 mg/kg/day (Fig. 2, 3, 4). 
This neurotoxic peptide leads to cognitive and 
behavioral disorders including spatial working 
memory and contextual long-term memory, as well 
as biochemical modifications such as lipid 
peroxidation. The effect inducing concentration of 
AT000 extract was significantly higher than the 
previously reported concentration for Amino-
tetrahydrofuran derivative ANAVEX1-41 [10 
μg/kg; [32]. However, ANAVEX1-41 was 
administered intraperitoneally suggesting that the 
mode of administration plays a role in determining 
the effective dose. Koo et al. and Jeon et al. studied 
the effect of SuHeXiang essential oil on attenuation 
of amyloid-beta-induced alteration of memory. 
However, their studies did not report an effective 
dose [24, 25]. On the other hand, oral 
administration in the present study showed an 
advantage over inhalation for the determination of 
an active dose of this extract in vivo for the first 
time. 
3.4 Experiment 3 (Evaluation of synergy)  
In this experiment, we evaluated the impact 
of Dryobalanops aromatica and Saussurea lappa 
in the composition to demonstrate synergy between 
the different plants constituting the AT000 extract. 
For this, we prepared 4 extracts by eliminating 
these two plants. We evaluated the neuroprotective 
effect of these 4 extracts on the attenuation of Aβ25-
35-induced learning deficits first with spatial 
working memory: spontaneous alternation in the Y-
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maze and contextual long-term memory: passive 
avoidance test. The impact of these extracts on lipid 
peroxidation in the hippocampus was also 
evaluated. This last experiment was performed at 
the active dose of the 21-days injection procedure. 
 
Figure 3. Effects of AT000 administration during 7 days (a, b) and 21 days (c, d) on Aβ25-35-induced 
passive avoidance deficits in mice: (a, c) step-through latency and (b, d) escape latency measured during 
the retention session. V, vehicle solution. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the V-treated Sc.Aβ 
group; ## p < 0.01, ### p < 0.001 vs. the Aβ25-35-treated group; Dunn's test. 
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Figure 4. Effects of AT000 administration during 7 days (a) and 21 days (b) on Aβ25-35-induced increase 
in lipid peroxidation in the mouse hippocampus. V, vehicle solution. *** p < 0.001 vs. the V-treated Sc.Aβ 
group; ## p < 0.01, ### p < 0.001 vs. the Aβ25-35-treated group; Dunn's test. 
 
3.4.1 Spontaneous alternation performances 
Spontaneous alternation in the Y-maze was 
evaluated first, as shown in Fig. 5a and 5b. Aβ25-35 
treatment induced highly significant spontaneous 
alternation deficits as compared to Sc.Aβ/V-
injected mice. The AT000 treatment blocked the 
Aβ25-35-induced deficit, when solubilized in 
Vehicle 1 solution (Fig. 5a) as well as in-vehicle 2 
solution (Fig. 5b). Neither the 1 or 2 plants 
formulations (AT001 or AT002) or the remaining 7 
or 8 plants formulations (AT007, AT008) affected 
the Aβ25-35-induced alternation deficit (Fig. 5b). No 
effect was noted on locomotion. 
 
Figure 5. Comparative effects of Dryobalanops aromatica, Saussurea lappa and AT formulations p.o. 
administration during 21 days on Aβ25-35-induced spontaneous alternation deficits in mice. Veh1, vehicle 
1 solution (DMSO 5% in water); Veh2, vehicle 2 solution (DMSO 10% in grapeseed oil). *** p < 0.001, 
** p < 0.01 vs. the V-treated Sc.Aβ group; ### p < 0.001 vs. the V-treated Aβ25-35 group; Dunnett's test.
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3.4.2 Step-through passive avoidance test 
The contextual long-term memory was evaluated 
using the step-through passive avoidance test. Aβ25-
35 treatment induced highly significant passive 
avoidance deficits as compared to Sc.Aβ/V-
injected mice, both regarding step-through latency 
(Fig. 6a, c) or escape latency (Fig. 6b, d). AT000 
treatment blocked the Aβ25-35-induced deficits 
when solubilized in Vehicle 1 solution (Fig. 6a, c) 
as well as in-vehicle 2 solution (Fig. 6b, d). Neither 
the 1 or 2 plants formulations (AT001 or AT002) 
or the remaining 7 or 8 plants formulations (AT007, 
AT008) affected the Aβ25-35-induced passive 
avoidance deficits, both in terms of step-through 
latency (Fig. 6a, c) or escape latency (Fig. 6b, d). 
 
Figure 6. Comparative effects of Dryobalanops aromatica, Saussurea lappa and AT formulations on 
Aβ25-35-induced passive avoidance deficits in mice: (a) step-through latency and (b) escape latency 
measured during the retention session. Veh1, vehicle 1 solution (DMSO 5% in water); Veh2, vehicle 2 
solution (DMSO 10% in grapeseed oil). ** p < 0.01, *** p < 0.001 vs. the V-treated Sc.Aβ group; ### p 
< 0.001 vs. the Aβ25-35-treated group; Dunn's test.
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3.4.3 Lipid peroxidation measure  
Finally, we evaluated lipid peroxidation, an index 
of oxidative stress. The Aβ25-35 treatment induced 
highly significant increase (+44%) in lipid 
peroxidation in the hippocampus, as compared to 
Sc.Aβ/V-injected mice in Veh1 conditions (Fig. 7a) 
and a highly significant increase (+63%) in lipid 
peroxidation in the hippocampus, as compared to 
Sc.Aβ/V-injected mice in Veh2 conditions (Fig. 
7a). AT000 treatment blocked the Aβ25-35-induced 
increase highly significantly as compared to Aβ25-
35/V-treated mice in both vehicle conditions (Fig. 
7a, b). Neither the 1 nor 2 plants formulations 
(AT001 or AT002) or the remaining 7 or 8 plants 
formulations (AT007, AT008) affected the Aβ25-35-
induced increase in lipid peroxidation (Fig. 7b).  
 
 
Figure 7. Comparative effects of Dryobalanops aromatica, Saussurea lappa, and AT formulations p.o. 
administration during 21 days on Aβ25-35-induced increase in lipid peroxidation in the mouse 
hippocampus. Veh1, vehicle 1 solution (DMSO 5% in water); Veh2, vehicle 2 solution (DMSO 10% in 
grapeseed oil). *** p < 0.001; ### p < 0.001 vs. the V-treated Aβ25-35 group; Dunnett's test. 
 
The synergistic effect of Dryobalanops 
aromatica and Saussurea lappa was evaluated. For 
this purpose, 4 different extracts were prepared to 
study the impact on the overall activity of the 
extract. The 4 extracts were tested on spatial 
working memory, contextual long-term memory 
and lipid peroxidation at the active dose (250 
mg/kg/day) and 21-days treatment. The results 
obtained showed that the elimination of these 
plants from the extract led to the total 
disappearance of the neuroprotective activity (Fig. 
5, 6, 7). The results also showed that Dryobalanops 
aromatica and Saussurea lappa alone do not show 
any neuroprotective activity. The activity is due to 
the combination of these 9 plants which, by 
extracting them together, will interact according to 
the potentiation and the effect will be boosted. 
Additionally, the two controversial plants were 
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found to be essential for the neuroprotective 
activity of the extract. 
The mechanisms of action of the plants 
constituting AT000 extract have been previously 
studied. Essential oil of Eugenia caryophyllata 
possesses anticonvulsant activity against maximal 
electroshock (MES)-induced tonic seizures in male 
mice [67]. Liquidambar orientalis has also been 
reported to have anticonvulsant and sedative 
properties by substantially delaying the appearance 
of PTZ-induced convulsion [68]. Aqueous extract 
of Aquilaria agallocha stems showed inhibitory 
effects on histamine release from rat peritoneal 
mast cells leading to inhibition of immediate 
hypersensitivity reactions [69]. Benzylacetone, α-
gurjunene and calarene, principles volatile obtained 
from Agarwood oil showed sedative activity in 
mice using a system of spontaneous vapor 
administration [70]. Alcoholic extract of Aquilaria 
agallocha (AEAA) has anticonvulsant activity 
using PTZ (Pentylenetetrazole) to induced 
convulsion. At a higher dose, an AEAA showed a 
significant anticonvulsant effect by increasing 
latency of clonus, an onset of tonic seizures and 
declined mortality of mice [71]. Cyperus rotundus 
tubers extract attenuated significantly learning and 
memory disturbance in passive avoidance 
paradigm and spatial cognitive deficit in Morris 
water maze produced by lesioning of the NBM in 
rats [72]. Cyperus rotundus tubers extract treatment 
showed therapeutic potential in aging and age-
related neurodegenerative disorders by preventing 
the cognitive impairments significantly following 
NBM lesion [72]. Pre-treatment of neurons with 
Cyperus rotundus extract ameliorates the 
mitochondrial and plasma membrane damage 
induced by SIN-1, restores the cellular morphology 
and improves the antioxidant status by regulating 
the oxidative stress biomarkers [73]. Total 
oligomeric flavonoids (TOFs) extracted from 
Cyperus rotundus demonstrated neuroprotective 
effect against the ischemic–reperfusion, induced 
neurodegeneration in the rat model by reducing 
oxidative stress, excitotoxicity, neurological and 
behavioral alterations [74]. Pre-treatment with an 
alcoholic extract of Saussurea lappa roots 
increased latency and also reduced mortality rate 
which indicates anticonvulsant property against 
Pentylenetetrazole and picrotoxin-induced 
convulsions in mice [75]. 
 
4. Conclusions 
Our results demonstrated that AT000 extract 
has a significant neuroprotective effect on the 
attenuation of the Aβ25-35-induced learning deficits 
and lipid peroxidation in the hippocampus. The 
extract also showed an effective antioxidant and 
anti-inflammatory activities, which indicates that 
AT000 extract has potential as a potent therapeutic 
agent for neuroprotection and prevention of AD. 
We are continuing studies on the AT000 extract to 
better understand the synergy mechanisms between 
the different plants in the mixture as well as 
chemical composition of AT000 extract. For that 
the analytical study part including the chemical 
composition of the plants is crucial.  
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